ad image

Company Info

Novartis

Novartis

Drug Discovery & Development

Overview

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. 
Novartis
Contributions
35 Contributions1 / 2
Novartis
Oral Therapy

Novartis Investigational Oral Therapy Iptacopan (Lnp023) Shows Benefit as Monotherapy in Treatment-Naïve Patients with Rare and Life-threatening Blood Disorder Paroxysmal Nocturnal Hemoglobinuria

Novartis

PR-M06-21-022Jun 17, 2021
Novartis
COVID-19 Treatment

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19

Novartis

PR-M06-21-003Jun 02, 2021
Novartis
FDA Approval

Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis

Novartis

PR-M06-21-002Jun 01, 2021
Novartis
Production

Novartis to Produce Roche's Actemra/RoActemra

Novartis

PR-M04-21-017Apr 19, 2021
Novartis

Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin Therapies for Potential Use Against COVID-19

Novartis

PR-M11-20-006Nov 06, 2020
Novartis

Novartis Launches First-of-its-Kind Not-for-Profit Portfolio of Medicines for Symptomatic Treatment of COVID-19

Novartis

PR-M07-20-NI-35Jul 24, 2020
Novartis
FDA Approval

Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14

Novartis

PR-M05-20-NI-011-1570May 07, 2020
Novartis
M&A

Novartis Acquires Amblyotech

Novartis

PR-M04-20-NI-039Apr 28, 2020
Novartis
COVID-19 Clinical Trials

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients

Novartis

PR-M04-20-NI-029Apr 20, 2020
Novartis
COVID-19 Clinical Study

Novartis Announces Plans to Initiate Clinical Study of Jakavi in Severe COVID-19 Patients

Novartis

PR-M04-20-NI-016Apr 10, 2020
Novartis
Priority Review

Novartis Lung Cancer Drug Granted Priority FDA Review

Novartis

PR-M02-20-NI-010Feb 11, 2020
Novartis
M&A

Novartis to Acquire The Medicines Company for $9.7 Billion

Novartis

PR-M11-19-NI-031Nov 25, 2019
Novartis
Approval

Novartis Gets European Approval to Update Cosentyx Label to Include Dosing Flexibility in Ankylosing Spondylitis

Novartis

PR-M10-19-NI-036Oct 25, 2019
Novartis
Collaboration

Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence

Novartis

PR-M10-19-NI-007Oct 02, 2019
Novartis

Novartis Stands Behind Zolgensma® (onasemnogene abeparvovec-xioi) for the Treatment of Children Less than 2 Years of Age with Spinal Muscular Atrophy

Novartis

PR-M08-19-NI-023Aug 08, 2019
Novartis
FDA Acceptance

FDA Accepts File and Accelerates Review of Novartis Sickle Cell Disease Medicine Crizanlizumab (SEG101)

Novartis

PR-M07-19-NI-048Jul 18, 2019
Novartis
Leadership

Novartis Announces New Leader of Pharmaceuticals Business Unit

Novartis

PR-M06-19-NI-024Jun 18, 2019
Novartis
Drug Development

Novartis Cosentyx® First to Show Efficacy in All Key Manifestations of Psoriatic Arthritis

Novartis

PR-M06-19-NI-020Jun 17, 2019
Novartis
M&A

Novartis to Acquire Xiidra®, Expanding Front-of-Eye Portfolio

Novartis

PR-M05-19-NI-034May 13, 2019
Novartis
FDA Acceptance

Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD

Novartis

PR-M04-19-NI-053Apr 17, 2019
1 / 2
0 Contributors1 / 0

No authors found

1 / 0